DeepMed Research

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

Phase 2

Recruiting

Conditions: Treatment
Immune Thrombocytopenia

Interventions: Drug: Obinutuzumab Injection [Gazyva]

First Posted Date: 2023-10-23

Last Posted Date: 2025-02-24

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 60

Registration Number: NCT06094881

Locations: 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

Phase 1

Not yet recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: chidamide
Drug: Venetoclax Oral Tablet
Drug: Inotuzumab Ozogamicin

First Posted Date: 2023-10-17

Last Posted Date: 2023-11-02

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 42

Registration Number: NCT06087419

Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy

Not Applicable

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Other: Different induction chemotherapy regimens

First Posted Date: 2023-10-04

Last Posted Date: 2024-08-12

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 90

Registration Number: NCT06066242

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells

Not Applicable

Recruiting

Conditions: Thalassemia, Beta
Thalassemia Major

Interventions: Biological: VGB-Ex01

First Posted Date: 2023-09-18

Last Posted Date: 2023-10-17

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 2

Registration Number: NCT06041620

Locations: 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China

The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

Phase 2

Recruiting

Conditions: Refractory/Relapsed Autoimmune Hemolytic Anemia

Interventions: Drug: Zanubrutinib

First Posted Date: 2023-09-01

Last Posted Date: 2023-11-29

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 33

Registration Number: NCT06021977

Locations: 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China

Anti-CD38 Antibody Treating Evans Syndrome

Phase 2

Recruiting

Conditions: Treatment
Evan Syndrome

Interventions: Drug: Anti-CD38 antibody Injection

First Posted Date: 2023-08-28

Last Posted Date: 2025-02-21

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 10

Registration Number: NCT06014775

Locations: 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia

Phase 2

Recruiting

Conditions: Immune Thrombocytopenia
Treatment

Interventions: Drug: Obinutuzumab Injection [Gazyva]

First Posted Date: 2023-08-16

Last Posted Date: 2025-02-21

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 110

Registration Number: NCT05995054

Locations: 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, China

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Phase 1

Not yet recruiting

Conditions: AML, Adult
Minimal Residual Disease

Interventions: Drug: CD33/CLL1 dual CAR-NK cell
Drug: Cyclophosphamid
Drug: Fludarabine
Drug: super NK cell
Drug: CD33 CAR-NK cell
Drug: Cytarabine

First Posted Date: 2023-08-14

Last Posted Date: 2023-08-14

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 102

Registration Number: NCT05987696

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy

Recruiting

Conditions: Gene Therapy
Transfusion-dependent Beta-Thalassemia

Interventions: Genetic: Gene therapy

First Posted Date: 2023-08-14

Last Posted Date: 2023-08-14

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 100

Registration Number: NCT05991336

Locations: 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China

Anti-CD38 Antibody Treating APS With Thrombocytopenia

Phase 2

Recruiting

Conditions: Antiphospholipid Syndrome
Thrombocytopenia

Interventions: Drug: Anti-CD38 antibody Injection

First Posted Date: 2023-08-09

Last Posted Date: 2025-02-21

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 10

Registration Number: NCT05983952

Locations: 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy